iiinova — where your digital self keeps evolving

Twitter history of @soragnilab @twitter.soragnilab.com · 03/10/2024

Good news/bad news day today.. Good news first! Our sarcoma organoid paper (www.cell.com/cell-stem-cell/fulltex…) is in officially out and published, and there is a very thoughtful commentary to accompany...

100

Twitter history of @soragnilab @twitter.soragnilab.com · 20/09/2024

Now, there are over 100 types of sarcoma (!), it is an incredibly diverse family of tumors. They are all rare and ultra-rare cancers, many without any type of model that allows us to study the biology and develop effective therapies.

000

Twitter history of @soragnilab @twitter.soragnilab.com · 20/09/2024

Organoids from almost any type of carcinoma have been developed, but non-epithelial cancers lagged behind - until now! Here is our paper developing patient-derived sarcoma organoids from 110+ samples, 20+ types of sarcomas, rare bone and soft tissue...

100

Twitter history of @soragnilab @twitter.soragnilab.com · 21/08/2024

Lots of good news to share on our NF1 work. Our platform to screen cutaneous neurofibroma organoids was recently published & we were awarded two grants from @ntapresearch and @GilbertFamilyFd to take these models to the next level. So proud of this...

100

Twitter history of @soragnilab @twitter.soragnilab.com · 11/07/2024

Our roadmap for the next generation of Children’s Oncology Group rhabdomyosarcoma trials acsjournals.onlinelibrary.wiley.com…

000

Twitter history of @soragnilab @twitter.soragnilab.com · 13/05/2024

Over the past few years, we have developed an approach to rapidly establish and screen 3D tumor organoids. We have deployed this approach to study fast growing or indolent malignant tumors. Now we translate it to cutaneous neurofibromas.

000

Twitter history of @soragnilab @twitter.soragnilab.com · 13/05/2024

There is no systemic therapy, and if the tumors cause any issue they need to be removed surgically for the most part. It is also a very challenging tumor type to model in the lab, as it is formed by many different cell types and abundant extracellular proteins.

100

Twitter history of @soragnilab @twitter.soragnilab.com · 13/05/2024

Neurofibromatosis type 1 is a common inherited disorder caused by alterations in the NF1 gene. One of the most penetrant features of the disease is the formation of these benign tumors, cutaneous neurofibromas, in the dermis. They can be anywhere in the body, and numerous.

100

Twitter history of @soragnilab @twitter.soragnilab.com · 13/05/2024

Here’s the thing about benign tumors. While they may not metastasize, they can still cause substantial health issues, particularly when they number in the hundreds, or thousands such as the case of cNFs in Neurofibromatosis type 1 patients.

100

Twitter history of @soragnilab @twitter.soragnilab.com · 13/05/2024

✨Very happy to share that we have a new paper published this morning that expands our high throughput organoid screening platform to a type of heterogenous, benign tumors called on cutaneous neurofibromas (cNFs). You can find it here:...

100

Twitter history of @soragnilab @twitter.soragnilab.com · 11/04/2024

We have a new collaborative paper out! Tweetorial to follow, but so excited to see this follow up to one of my PhD/postdoc projects: www.cell.com/cell-reports/fulltext/…

000

Twitter history of @soragnilab @twitter.soragnilab.com · 08/04/2024

The eclipse is not the only cool thing happening today.. join us in one hour! #AACR24

000

Twitter history of @soragnilab @twitter.soragnilab.com · 08/04/2024

It's finally organoids day at #AACR24!! Join us for the AT05 session at 12:30pm in Ballroom CD to see how we use tumor organoids for immunooncology, for rare tumors modeling and precision medicine, for undestanding tumor...

100

Twitter history of @soragnilab @twitter.soragnilab.com · 07/04/2024

Love to hear about the motivation behind the seven new advances in technology sessions at #AACR24 from this year meeting co-chair, Dr. Cristina Curtis. Putting together a program for such a meeting is a behemoth challenge, congrats @cncurtis and Dr. Flaherty on an amazing job!

000

Twitter history of @soragnilab @twitter.soragnilab.com · 07/04/2024

Still unbelievable and heartbreaking to see @TaniguchiMD in the ad memoriam segment at #AACR24 💔

000

Twitter history of @soragnilab @twitter.soragnilab.com · 04/04/2024

We have a new lab website!! So happy that www.soragnilab.com is now live, and in time for #AACR24. I am very thankful to the entire @stellatecomms team that turned my vision into a coherent reality! Have a look around and let me know what you think

soragnilab.com

Soragni Lab - Home

The Soragni Lab at UCLA investigates protein aggregation ...

000

Twitter history of @soragnilab @twitter.soragnilab.com · 01/04/2024

It's almost time for the annual AACR meeting and y'all know what that means..... .......tax season is upon us!! 😆 Jokes aside, very excited for this year's meeting, lots of incredibly cool science, tons of networking. Will be sharing our work soon as well!

000

Twitter history of @soragnilab @twitter.soragnilab.com · 29/03/2024

Incredibly humbled and grateful for the C2C's team efforts in fundraising for our pediatric sarcoma research. C2C is spearheaded by a group of fantastic teen advocates, check out their fundraising page to learn more about their amazing work and motivation: givebutter.com/c2c

givebutter.com

Chords2Cure 2024

Raising funds for pediatric cancer research at UCLA

000

Twitter history of @soragnilab @twitter.soragnilab.com · 07/03/2024

Celebrating a fantastic yet totally unfundable 12% today 😀😩🙃😀

000

Twitter history of @soragnilab @twitter.soragnilab.com · 13/12/2023

We are re-doing our lab website and would love to hear what resonates with people the most. Any awesome lab website examples to share??

000

Twitter history of @soragnilab @twitter.soragnilab.com · 11/12/2023

Very beautiful, exciting work from @TalyaDayton characterizing drug dependencies in neuroendocrine tumors www.cell.com/cancer-cell/fulltext/S…

000

Twitter history of @soragnilab @twitter.soragnilab.com · 02/08/2023

Seventh consecutive seminar invite sent out, accepted and scheduled. All are women. It's not that hard, is it.

000

Twitter history of @soragnilab @twitter.soragnilab.com · 27/06/2023

People have their own motives so no judgment but personally I enjoy presenting unpublished data for early feedback

000

Twitter history of @soragnilab @twitter.soragnilab.com · 27/06/2023

In my experience there are two types of scientists. Those that freely present unpublished data with little to no reservation and those who don’t. Mandated policies rarely make a difference as the divide is large.

100

Twitter history of @soragnilab @twitter.soragnilab.com · 27/06/2023

Are Gordon Research Conferences still following Fight Club rules?

000

Twitter history of @soragnilab @twitter.soragnilab.com · 07/06/2023

One of my favorite things about @UCLAJCCC is synergizing with other teams to make the best out of our individual expertise and develop bigger and better ways to solve big challenges in cancer - it's a great place to be! So on we go, to develop a platform to measure resistance

000

Twitter history of @soragnilab @twitter.soragnilab.com · 07/06/2023

Now just our luck, one of the foremost experts on this method, @teitell is a close collaborator and just a couple buildings down the road! The platform they build allows us to estimate the mass of measured objects, at single organoid resolution, with time resolved measurements

100

Twitter history of @soragnilab @twitter.soragnilab.com · 07/06/2023

The first thing we wanted to do, was find a method to monitor organoid response to therapy that was non invasive (label free preferred!), real-time and allowed us to monitor thousands of organoids at a time. The answer? High speed live cell interferometry

100

Twitter history of @soragnilab @twitter.soragnilab.com · 07/06/2023

Have talked about all the open data and code, now time for the science! Why did we decide to develop a new, 3D organoid drug screening platform? To chase one of the biggest issues behind treatment failure and tumor recurrence: those few drug resistant cells surviving treatment 🧵

100

Twitter history of @soragnilab @twitter.soragnilab.com · 06/06/2023

If you are looking to find a home for your data, check out this great resource by @michaelhoffman and colleagues: febs.onlinelibrary.wiley.com/doi/10…

000

Twitter history of @soragnilab @twitter.soragnilab.com · 06/06/2023

I am not discounting the effort it took to package everything and also find ways to share (for free) some of our less conventional data types - but it was the right thing to do for us

100

Twitter history of @soragnilab @twitter.soragnilab.com · 06/06/2023

It's fantastic not to have to worry about having to keep data safe somewhere, having to find it and come up with a way to share it if someone asks, etc etc "Data available on reasonable request" is no more :)

100

Twitter history of @soragnilab @twitter.soragnilab.com · 06/06/2023

Bunch of grants and papers being reviewed or re-reviewed soon.. May the peer review gods be with us 🫡

000

Twitter history of @soragnilab @twitter.soragnilab.com · 31/05/2023

Very proud of William who today successfully defended his Master thesis and graduated from @DominguezHills. First Master out of the lab!

000

Twitter history of @soragnilab @twitter.soragnilab.com · 29/05/2023

Apropos of nothing, here is your periodic reminder to avoid posting very specific details of what annoys you as a grant reviewer because it's NIH grant review season so it's obviously not likely a general example and people can figure things out

000

Twitter history of @soragnilab @twitter.soragnilab.com · 26/05/2023

Our sarcoma organoid pipeline preprint is out. This was a real tour de force, very thankful to everyone involved, from my lab, to collaborators and patients. Tweetorial to follow, and if you read and have comments or suggestions, reach...

100